OR WAIT 15 SECS
Enterprise Therapeutics is the recipient of funding worth up to £5.7 million (US $7 million) from the Cystic Fibrosis Foundation.
Biopharmaceutical company, Enterprise Therapeutics, is the recipient of funding worth up to £5.7 million (US $7 million) from the Cystic Fibrosis Foundation, which will be used to support the clinical development up to end of Phase II for a cystic fibrosis treatment.
The milestone-related funding, which has been granted under the Therapeutics Development Award program, will support the development of ETD002-a first-in-class TMEM16A potentiator. This therapy has the potential to treat all forms of cystic fibrosis as it targets the underlying mechanisms of mucus congestion, in this instance the calcium-activated chloride ion channel TMEM16A. Through enhancing the activity of the channel anion and fluid flow into the airways can be improved, which will thin mucus and enable its clearance from the airways more easily.
“We are delighted to receive such a significant award from the CF Foundation. This funding will enable critical clinical research to be undertaken on our novel TMEM16A programme, and highlights the potential of chloride channel modulation via alternative channels to deliver innovative and effective treatments for all CF patients,” said John Ford, CEO, Enterprise Therapeutics, in an Oct. 15, 2019 press release.
Source: Enterprise Therapeutics